Literature DB >> 16107883

G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.

Gilles Doumont1, Alain Martoriati, Chantal Beekman, Sven Bogaerts, Patrick J Mee, Fabrice Bureau, Emanuela Colombo, Myriam Alcalay, Eric Bellefroid, Francesco Marchesi, Eugenio Scanziani, Pier Giuseppe Pelicci, Jean-Christophe Marine.   

Abstract

In response to DNA damage, p53 activates a G1 cell cycle checkpoint, in part through induction of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1). Here we report the identification of a new direct p53 target, Ptprv (or ESP), encoding a transmembrane tyrosine phosphatase. Ptprv transcription is dramatically and preferentially increased in cultured cells undergoing p53-dependent cell cycle arrest, but not in cells undergoing p53-mediated apoptosis. This observation was further confirmed in vivo using a Ptprv null-reporter mouse line. A p53-responsive element is present in the Ptprv promoter and p53 is recruited to this site in vivo. Importantly, while p53-dependent apoptosis is intact in mice lacking Ptprv, Ptprv-null fibroblasts and epithelial cells of the small intestine are defective in G1 checkpoint control. Thus, Ptprv is a new direct p53 target and a key mediator of p53-induced cell cycle arrest. Finally, Ptprv loss enhances the formation of epidermal papillomas after exposure to chemical carcinogens, suggesting that Ptprv acts to suppress tumor formation in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107883      PMCID: PMC1201350          DOI: 10.1038/sj.emboj.7600769

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  49 in total

1.  Definition of a consensus binding site for p53.

Authors:  W S el-Deiry; S E Kern; J A Pietenpol; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

2.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

4.  Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.

Authors:  S W Lowe; T Jacks; D E Housman; H E Ruley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53.

Authors:  Alain Martoriati; Gilles Doumont; Myriam Alcalay; Eric Bellefroid; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

6.  In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice.

Authors:  M Harvey; A T Sands; R S Weiss; M E Hegi; R W Wiseman; P Pantazis; B C Giovanella; M A Tainsky; A Bradley; L A Donehower
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

7.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

8.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

Authors:  C J Kemp; L A Donehower; A Bradley; A Balmain
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

9.  Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.

Authors:  C Deng; P Zhang; J W Harper; S J Elledge; P Leder
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

10.  Radiation-induced cell cycle arrest compromised by p21 deficiency.

Authors:  J Brugarolas; C Chandrasekaran; J I Gordon; D Beach; T Jacks; G J Hannon
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

View more
  16 in total

1.  Variations in target gene expression and pathway profiles in the mouse hippocampus following treatment with different effective compounds for ischemia-reperfusion injury.

Authors:  Yinying Chen; Caixiu Zhou; Yanan Yu; Jun Liu; Zhiwei Jing; Aiping Lv; Fanyun Meng; Zhong Wang; Yongyan Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-24       Impact factor: 3.000

Review 2.  Deconstructing networks of p53-mediated tumor suppression in vivo.

Authors:  Alyssa M Kaiser; Laura D Attardi
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

Review 3.  Deconstructing p53 transcriptional networks in tumor suppression.

Authors:  Kathryn T Bieging; Laura D Attardi
Journal:  Trends Cell Biol       Date:  2011-12-09       Impact factor: 20.808

4.  Editor's Highlight: Hydroxyurea Exposure Activates the P53 Signaling Pathway in Murine Organogenesis-Stage Embryos.

Authors:  Nazem El Husseini; Ava E Schlisser; Barbara F Hales
Journal:  Toxicol Sci       Date:  2016-05-13       Impact factor: 4.849

5.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

6.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.

Authors:  Sarah Francoz; Pascal Froment; Sven Bogaerts; Sarah De Clercq; Marion Maetens; Gilles Doumont; Eric Bellefroid; Jean-Christophe Marine
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 7.  Tumor-Suppressor Functions of the TP53 Pathway.

Authors:  Brandon J Aubrey; Andreas Strasser; Gemma L Kelly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

8.  Unravelling mechanisms of p53-mediated tumour suppression.

Authors:  Kathryn T Bieging; Stephano Spano Mello; Laura D Attardi
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

9.  FTO mediates cell-autonomous effects on adipogenesis and adipocyte lipid content by regulating gene expression via 6mA DNA modifications.

Authors:  Jayne F Martin Carli; Charles A LeDuc; Yiying Zhang; George Stratigopoulos; Rudolph L Leibel
Journal:  J Lipid Res       Date:  2018-06-22       Impact factor: 5.922

10.  Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53.

Authors:  V C Padmakumar; Eiman Aleem; Cyril Berthet; Mary Beth Hilton; Philipp Kaldis
Journal:  Mol Cell Biol       Date:  2009-03-23       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.